<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 - 11:00</td>
<td>Epidemiology / Prevention / Health promotion / Physical Activity / Advocacy</td>
</tr>
<tr>
<td>11:00 - 12:00</td>
<td>Genetics / Epigenetics / Technology / E-Health</td>
</tr>
<tr>
<td>12:00 - 13:00</td>
<td>Hypertension / Obesity / Dyslipidemia / Diabetes and Metabolic Disorders</td>
</tr>
<tr>
<td>13:00 - 14:00</td>
<td>Heart Failure / Left Ventricular Function / Myocardial Pericardial Disease / Chagas Disease</td>
</tr>
<tr>
<td>14:00 - 15:00</td>
<td>Arrhythmias / Vascular Disease / RHD / Pulmonary Circulation / Valvular Intervention</td>
</tr>
<tr>
<td>15:00 - 16:00</td>
<td>Ischaemia / Coronary Artery Disease / Coronary Interventions / Acute Coronary Syndrome / Stroke / Peripheral Circulation / Non-Coronary Interventions / Aorto-Arteritis</td>
</tr>
<tr>
<td>16:00 - 17:00</td>
<td>Cardiac Imaging / Paediatrics / Adolescent / Congenital heart disease</td>
</tr>
<tr>
<td>17:00 - 18:00</td>
<td>WELCOME CEREMONY</td>
</tr>
<tr>
<td>18:00 - 19:00</td>
<td>WELCOME RECEPTION IN THE EXHIBITION HALLS</td>
</tr>
<tr>
<td>19:00 - 20:00</td>
<td>Allied Health Professionals</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td>08:00 - 09:00</td>
<td>Plenary Session</td>
</tr>
<tr>
<td>09:00 - 10:00</td>
<td>Novel Therapies to Reduce Cardiovascular Risk</td>
</tr>
<tr>
<td>10:00 - 11:00</td>
<td>The Role of Imaging in Prevention</td>
</tr>
<tr>
<td>11:00 - 12:00</td>
<td>Glycemic and Lipid Metabolic Disorders</td>
</tr>
<tr>
<td>12:00 - 13:00</td>
<td>Strengthening Primary Healthcare - Community Based Vascular Prevention &amp; Management across the Globe</td>
</tr>
<tr>
<td>13:00 - 14:00</td>
<td>Taped case - Valvular Disease</td>
</tr>
<tr>
<td>14:00 - 15:00</td>
<td>Plenary Session</td>
</tr>
<tr>
<td>15:00 - 16:00</td>
<td>Plenary Session</td>
</tr>
<tr>
<td>16:00 - 17:00</td>
<td>Plenary Session</td>
</tr>
<tr>
<td>17:00 - 18:00</td>
<td>Plenary Session</td>
</tr>
</tbody>
</table>

**LUNCH & INDUSTRY SATELLITES**

- **Guidelines in a Nutshell**
- **Diabetes and Metabolic Disorders**
- **Surgical Options**
- **Epidemiology**
- **Non-Coronary Interventions**
- **Genetics and Global CVD Burden**
- **Thrombolysis**
- **Risk Stratification & Prediction of Events**
- **CVD in Adolescents in Low-Income Settings**
- **Rheumatic Fever**
- **Imaging in HCM: Case Illustration**
- **Stroke prevention in atrial fibrillation**
- **High Density Lipoproteins: The Good, The Bad, The Ugly**
- **Ischemic stroke**
- **Rheumatic Heart Disease: Nurses taking up the Challenge**
- **Salt Consumption and Cardiovascular Health**
- **The Best Diet to Reduce Cardiovascular Risk**

**BREAK**

**Putting Guidelines in Clinical Context**

**Genetics and Global CVD Burden**

- Where is the genetics in global picture
- Genetics of coronary artery disease
- Has genetics helped in understanding of CVD vs factor X?

**Trials and Value Disease: Trials and Value Disease**

- New hopes for the ‘forgotten’ value
- Underlying theme of phase II trials
- Understanding safety in an economic context
- Assessment of trial value
- Surgical and transcatheter treatments

**Risk Stratification & Prediction of Events**

- Primary Prevention - Predict CAD vs. Screening CAD
- Predict Myocardial Infarction - Who is at risk when is it unclear
- Chronic Stable CAD - How do we stratify for Risk and Choosing Therapy
- Should Risk Prediction Paradigms be different in LMIC’s

**CVD in Adolescents in Low-Income Settings**

- How to adopt a patient-centred pathway experience
- Assessing the feasibility of new therapies or imaging
- Role of interventional cardiology in LMIC’s
- Managing complex RHD in pregnancy in LMIC

**Rheumatic Fever**

- What is new, novel and innovation - CC
- What is the latest in vitamin K antagonist
- What is the latest in biologicals
- What is the latest in surgery

**Improving Patient Experience with CVD Risk Reduction: The Role of Technology - MTE**

- What is the role of technology in the patient journey
- The role of technology and the patient journey
- The role of technology in the patient journey
- The role of technology in the patient journey
- The role of technology in the patient journey
- The role of technology in the patient journey

**The Best Diet to Reduce Cardiovascular Risk**

- Focus on Cholesterol saturated fats - This is why Japanese have the lowest cardiovascular risk
- Focus on Cholesterol single carboidrates and consuming Good Fats - This is why Israeli/Mediterranean countries have a lower risk of CAD
- Focus on Cholesterol single carbohydrates and consuming Good Fats - This is why Israeli/Mediterranean countries have a lower risk of CAD

**Rheumatic Heart Disease: Nurses taking up the Challenge**

- Nurses in leadership and decision-making
- Challenges interwoven pathways to patients in LMIC settings
- Challenges presented to nurses in secondary prophylaxis
- Global Heart Health: Nurse leaders in LMIC
- Nurse leaders in LMIC

**Salt Consumption and Cardiovascular Health**

- What is the latest in vitamin K antagonist
- What is the latest in biologicals
- What is the latest in surgery

**The Best Diet to Reduce Cardiovascular Risk**

- Focus on Cholesterol saturated fats - This is why Japanese have the lowest cardiovascular risk
- Focus on Cholesterol single carbohydrates and consuming Good Fats - This is why Israeli/Mediterranean countries have a lower risk of CAD
- Focus on Cholesterol single carbohydrates and consuming Good Fats - This is why Israeli/Mediterranean countries have a lower risk of CAD

**Rheumatic Fever**

- What is new, novel and innovation - CC
- What is the latest in vitamin K antagonist
- What is the latest in biologicals
- What is the latest in surgery

**Improving Patient Experience with CVD Risk Reduction: The Role of Technology - MTE**

- What is the role of technology in the patient journey
- The role of technology and the patient journey
- The role of technology in the patient journey
- The role of technology in the patient journey
- The role of technology in the patient journey
- The role of technology in the patient journey
### Myths about diet and CVD

**Speaker:** Sathu Noul

#### New Frontiers in Cardiac Rehabilitation and Secondary Prevention
- Preventing Sudden Cardiac Death
  - Risk factors and sudden cardiac death: a global update
  - Devices for global prevention of sudden death
  - Do antiarrhythmics drugs carry value for prevention of sudden death?

#### Prevention of Sudden Cardiac Death
- Atrial fibrillation
- Mitral regurgitation: primary versus functional
- Rheumatic MS and VPMP. Is there anything new?
- Low flow low gradient AS with preserved EF. How do we deal with it?

#### Cardiac Disease in Pregnancy - MTE
- Preventing Cardiovascular Events in Special Populations: Cancer, HIV, etc...
- New Models of Cardiac Rehabilitation: Do They Truly Work?
- Improving Referral, Availability, and Payment for Cardiac Rehabilitation:
  - Recent clinical Trials in Imaging: Ventricular Remodelling and Hypertensive Heart Disease
  - High flow high gradient AS with preserved EF. How do we deal with it?

#### Imaging in Valvular Heart Disease
- Low flow-low gradient AS with preserved EF. How do we deal with it?
- Valve replacement in the elderly: How can we avoid leaflet/annulus distortion?
- Rheumatic MS and MVP: is there anything new?
- Mitral regurgitation: primary vs. functional

## LUNCH & INDUSTRY SATELLITES

### CVD and Women

**Speaker:** Nanette Wenger

#### Advances in CVD Genetics
- Atrial fibrillation
- Vascular amyloids
- Familial variants: 18/1000. A 25 year history

#### Recent clinical Trials in Imaging: Ventricular Remodelling and Hypertensive Heart Disease
- How Low Should You Go? BP, Lipids and Sugar
- Novel Risk factors for CAD
- What Is Optimal Risk Factor Control in Various Stages Of CAD?

#### Cardiac Stroke
- Cardiac causes of ischemic stroke
- The quality of stroke prevention in different countries
- Acute stroke in atrial fibrillation: risk stratification scheme

#### Rheumatic Heart Disease - Basic Science - SYM
- Current advances in the management of rheumatic heart disease
- Managing the patient with rheumatic heart disease: what is new?

#### Optimal Medical Therapy in Acute and Chronic CAD - MTE
- Novel Risk Factor Management
  - The role of the ESC in Establishing Framers in Global Leadership
- Strategies for reducing cardiovascular events
- The role of the ESC in Establishing Framers in Global Leadership

#### Polypill or Individual Risk Factor Management - D
- The Polypill is the way to go.
- One Size Does Not Fit All - Augmenting Against the Polypill

### ALLIED HEALTH PROFESSIONALS

#### Epidemiology / Prevention / Health promotion / Physical Activity / Advocacy
- Heart Failure / Left Ventricular Function / Myocardial Pericardial Disease / Chagas Disease

#### Genetics / Epigenetics / Technology / E-Health
- Amyotrophies

#### Hypertension / Obesity / Dyslipidemia / Diabetes and Metabolic Disorders
- Vascular Disease / RHD / Pulmonary Circulation / Valvular Intervention

#### Cardiology
- Ischaemia / Coronary Artery Disease / Coronary Interventions / Acute Coronary Syndrome
- Stroke / Peripheral Circulation / Non-Coronary Interventions / Aorta-Arteritis
- Cardiac Imaging

#### Paediatrics / Adolescent / Congenital heart disease
- Heart Disease in Women
- Heart Health Professionals

#### Cardiovascular Disease - D
- Management? - D
**Cardiac imaging in 2030: Predicting the future**
- Will there be a 3D LVEF in 2030?
- Will CMR be done for every cardiomyopathy?
- Can 3D echo be used more often?

**Controversies in Hypertension**
- What does HFrEF mean in hypertensive cardiomyopathy?
- How do we make the differential diagnosis between arterial hypertension and cardiomyopathy?

**Practical approaches for unique cases**
- Challenges in managing patients with Connective Tissue Disease
- The importance of ICDs in those with cardiomyopathy

**Rheumatic Heart Disease Prevention - SYM**
- The role of echocardiography in the diagnosis of rheumatic heart disease
- Challenges in managing patients with Connective Tissue Disease

**Controversies and Difficult Patient Management – HFpEF, HFrEF – MTE**
- Debates on the management of coronary artery disease
- Medical therapy for asymptomatic carotid stenosis: how effective is it?

**CVD in Women: Is it different? – CC**
- How does gender make a difference?
- Hypoglycemic medications and their impact on CV risk. Do age and gender make a difference?

**Hypertension / Obesity / Dyslipidemia / Genetics / Epigenetics / Technology / E-Health / Physical Activity / Advocacy / Epidemiology / Prevention / Health promotion / Allied Health Professionals**

**Epidemiology / Prevention / Health promotion / Physical Activity / Advocacy**
- Epidemiology / Prevention / Health promotion / Physical Activity / Advocacy

**Valvular Disease / RHD / Pulmonary Circulation / Arrhythmias**
- Controversies in Hypertension
- Rheumatic Heart Disease Prevention - SYM

**Non-Coronary Interventions / Aorto-Arteritis**
- Cardiac imaging in 2030: Predicting the future
- Controversies in Hypertension

**Coronary Interventions / Acute Coronary Syndrome**
- Cardiac imaging in 2030: Predicting the future
- Controversies in Hypertension

**Hypertension / Obesity / Dyslipidemia / Genetics / Epigenetics / Technology / E-Health / Physical Activity / Advocacy / Epidemiology / Prevention / Health promotion / Allied Health Professionals**

**Implantable Cardiac Devices**
- Opening of the symposium on CMR
- Challenges in managing patients with Connective Tissue Disease
- The importance of ICDs in those with cardiomyopathy

**Advances in EP Devices**
- Challenges in the diagnosis of rheumatic fever
- Challenges in the diagnosis of rheumatic fever

**Cardiac Imaging**
- Imaging in 2030: Predicting the future
- Controversies in Hypertension

**Controversies and Difficult Patient Management – HFpEF, HFrEF – MTE**
- Debates on the management of coronary artery disease
- Medical therapy for asymptomatic carotid stenosis: how effective is it?

**CVD in Women: Is it different? – CC**
- How does gender make a difference?
- Hypoglycemic medications and their impact on CV risk. Do age and gender make a difference?

**Hypertension / Obesity / Dyslipidemia / Genetics / Epigenetics / Technology / E-Health / Physical Activity / Advocacy / Epidemiology / Prevention / Health promotion / Allied Health Professionals**

**Epidemiology / Prevention / Health promotion / Physical Activity / Advocacy**
- Epidemiology / Prevention / Health promotion / Physical Activity / Advocacy

**Valvular Disease / RHD / Pulmonary Circulation / Arrhythmias**
- Controversies in Hypertension
- Rheumatic Heart Disease Prevention - SYM

**Non-Coronary Interventions / Aorto-Arteritis**
- Cardiac imaging in 2030: Predicting the future
- Controversies in Hypertension

**Coronary Interventions / Acute Coronary Syndrome**
- Cardiac imaging in 2030: Predicting the future
- Controversies in Hypertension

**Hypertension / Obesity / Dyslipidemia / Genetics / Epigenetics / Technology / E-Health / Physical Activity / Advocacy / Epidemiology / Prevention / Health promotion / Allied Health Professionals**

**Implantable Cardiac Devices**
- Opening of the symposium on CMR
- Challenges in managing patients with Connective Tissue Disease
- The importance of ICDs in those with cardiomyopathy

**Advances in EP Devices**
- Challenges in the diagnosis of rheumatic fever
- Challenges in the diagnosis of rheumatic fever

**Cardiac Imaging**
- Imaging in 2030: Predicting the future
- Controversies in Hypertension

**Controversies and Difficult Patient Management – HFpEF, HFrEF – MTE**
- Debates on the management of coronary artery disease
- Medical therapy for asymptomatic carotid stenosis: how effective is it?

**CVD in Women: Is it different? – CC**
- How does gender make a difference?
- Hypoglycemic medications and their impact on CV risk. Do age and gender make a difference?